Holen Sie sich die Stockscreener-App
1.01
2.86%
-0.04
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
California Biotech Reports Positive QOL Improvements in Program - Streetwise Reports
Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment - Streetwise Reports
Insider Selling: Attar Eyal C., Vor Biopharma Inc [VOR] CHIEF MEDICAL OFFICER divested 14,645 shares - Knox Daily
A better buy-in window may exist right now for Vor Biopharma Inc (VOR) - SETE News
Analytical Lens: Exploring Vor Biopharma Inc (VOR)’s Financial Story Through Ratios - The Dwinnex
VOR’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely - Simply Wall St
Biotech Working on 'Functional Cure' for Type 1 Diabetes - Streetwise Reports
MA Biotech Reports Positive Meeting with FDA - Streetwise Reports
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
How did Vor Biopharma Inc (VOR) fare last session? - US Post News
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $10.92 - MarketBeat
JMP Securities Reiterates Market Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
HC Wainwright Reiterates “Buy” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Principal Financial Group Inc. Has $10.28 Million Position in Molson Coors Beverage (NYSE:TAP) - Defense World
Thesis Gold (CVE:TAU) PT Raised to C$3.00 - Defense World
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? - MSN
Vor Biopharma (NYSE:VOR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Vor’s stem cell transplant delays cancer relapse - BioWorld Online
Vor Biopharma Inc (VOR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Mass. Biopharma Reports Positive Data & Announces New Program - Streetwise Reports
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? - Benzinga
Vor Biopharma stock holds price target, buy rating on positive study data - Investing.com
Ncino Inc. [NCNO] stock for 19,355 USD was sold by Orenstein Gregory - Knox Daily
A company insider recently sold 7,500 shares of Ardelyx Inc [ARDX]. Should You Sale? - Knox Daily
CHIEF MEDICAL OFFICER Attar Eyal C. sold 14,645 shares of Vor Biopharma Inc [VOR] - Knox Daily
Gaining Ground: Vor Biopharma Inc (VOR) Closes Lower at 0.82, Down -2.37 - The Dwinnex
Baird reiterates Outperform on Vor Biopharma as trem-cel data derisks safety profile - Investing.com
Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg? - Marketscreener.com
Vor Bio reports promising AML treatment data - Investing.com India
Aqua Metals Inc [AQMS] Shares Fall Approximately -81.89% Over the Year - Knox Daily
Vor Bio reports promising AML treatment data - Investing.com
Vor Bio stock rallies post-market on trem-cel study data (NASDAQ:VOR) - Seeking Alpha
Vor Biopharma Advances Innovative Blood Cancer Therapies - TipRanks
Vor Bio reports promising AML treatment data By Investing.com - Investing.com UK
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies - GlobeNewswire
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies - Yahoo Finance
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Dundee (TSE:DC.A) Shares Cross Above 50 Day Moving Average of $1.34 - Defense World
Examining Vor Biopharma Inc (VOR) stock is warranted - US Post News
Vor Biopharma Inc (VOR) expanding its growth trajectory ahead - SETE News
Vor Biopharma faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Vor Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences - Marketscreener.com
Vor Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
PureTech Health plc – Half-Year Report - Business Wire
Investing in Vor Biopharma Inc (VOR) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Vor Biopharma Inc (VOR) stock: A year of ups and downs - US Post News
Vanguard Group Inc. Has $4.30 Million Holdings in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Vor Biopharma Inc. (NYSE:VOR) Receives $10.92 Consensus PT from Brokerages - Defense World
Financial Survey: B.O.S. Better Online Solutions (NASDAQ:BOSC) versus Invent Ventures (OTCMKTS:IDEA) - Defense World
SiTime (NASDAQ:SITM) vs. STMicroelectronics (NYSE:STM) Head-To-Head Review - Defense World
Aptose Biosciences (NASDAQ:APTO) vs. ImmunityBio (NASDAQ:IBRX) Critical Review - Defense World
Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Target Price at $12.00 - Defense World
Vor Biopharma (NYSE:VOR) Price Target Cut to $3.00 by Analysts at Barclays - Defense World
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewswire
Vor Biopharma Inc. (NYSE:VOR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Vor Biopharma (NYSE:VOR) Price Target Cut to $3.00 by Analysts at Barclays - MarketBeat
Xeris Biopharma director buys $10.1k in company shares - Investing.com India
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024 - InvestorPlace
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update - Yahoo Finance
Anterix (ATEX) Set to Announce Quarterly Earnings on Tuesday - Defense World
Vor Biopharma stock hits 52-week low at $0.89 amid market challenges - Investing.com India
Vor Biopharma stock hits 52-week low at $0.89 amid market challenges - Investing.com
1.25%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):